Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001023250 | SCV001185099 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-03-26 | criteria provided, single submitter | clinical testing | The p.Q164* variant (also known as c.490C>T), located in coding exon 4 of the AIP gene, results from a C to T substitution at nucleotide position 490. This changes the amino acid from a glutamine to a stop codon within coding exon 4. One study found that this mutation drastically reduced the protein-protein binding activity of the AIP protein and identified this alteration in 1/38 familial isolated pituitary adenoma (FIPA) families (Igreja S et al. Hum. Mutat., 2010 Aug;31:950-60). This mutation has also been reported in additional individuals with FIPA (Hernández-Ramírez LC et al. J. Clin. Endocrinol. Metab., 2015 Sep;100:E1242-54) and in a German patient with acromegaly and pituitary macroadenoma diagnosed at age 18 (Schöfl C et al. J. Clin. Endocrinol. Metab., 2014 Dec;99:E2789-93). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Gene |
RCV000034084 | SCV000058014 | not provided | Somatotroph adenoma | no assertion provided | literature only |